Recent news headlines regarding X4 Pharmaceuticals focus on the European Commission granting marketing authorization for their flagship drug, XOLREMDI, as the first authorized treatment for WHIM syndrome within the European Union, with commercialization managed by their partner Norgine. Additional updates highlight the ongoing progression of their global Phase 3 clinical trials evaluating mavorixafor for chronic neutropenia and positive corporate earnings reports featuring increased full-year revenue projections.